Shah NP - Search Results

1

Michor F, Hughes TP, Iwasa Y, Branford S, Shah NP, Sawyers CL, Nowak MA. Michor F, et al. Among authors: shah np. Nature. 2005 Jun 30;435(7046):1267-70. doi: 10.1038/nature03669. Nature. 2005. PMID: 15988530

2

Recent success with the tyrosine kinase inhibitor STI-571--lessons for targeted therapy of cancer.

Shah NP, Sawyers CL. Shah NP, et al. Curr Opin Investig Drugs. 2001 Mar;2(3):422-3. Curr Opin Investig Drugs. 2001. PMID: 11575716 Review. No abstract available.

3

Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop.

Roumiantsev S, Shah NP, Gorre ME, Nicoll J, Brasher BB, Sawyers CL, Van Etten RA. Roumiantsev S, et al. Among authors: shah np. Proc Natl Acad Sci U S A. 2002 Aug 6;99(16):10700-5. doi: 10.1073/pnas.162140299. Epub 2002 Jul 29. Proc Natl Acad Sci U S A. 2002. PMID: 12149456 Free PMC article.

4

Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia.

Shah NP, Nicoll JM, Nagar B, Gorre ME, Paquette RL, Kuriyan J, Sawyers CL. Shah NP, et al. Cancer Cell. 2002 Aug;2(2):117-25. doi: 10.1016/s1535-6108(02)00096-x. Cancer Cell. 2002. PMID: 12204532 Free article.

5

Mechanisms of resistance to STI571 in Philadelphia chromosome-associated leukemias.

Shah NP, Sawyers CL. Shah NP, et al. Oncogene. 2003 Oct 20;22(47):7389-95. doi: 10.1038/sj.onc.1206942. Oncogene. 2003. PMID: 14576846 Review.

6

Overriding imatinib resistance with a novel ABL kinase inhibitor.

Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL. Shah NP, et al. Science. 2004 Jul 16;305(5682):399-401. doi: 10.1126/science.1099480. Science. 2004. PMID: 15256671

7

Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment.

Chu S, Xu H, Shah NP, Snyder DS, Forman SJ, Sawyers CL, Bhatia R. Chu S, et al. Among authors: shah np. Blood. 2005 Mar 1;105(5):2093-8. doi: 10.1182/blood-2004-03-1114. Epub 2004 Sep 2. Blood. 2005. PMID: 15345592 Free article.

8

Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance.

Burgess MR, Skaggs BJ, Shah NP, Lee FY, Sawyers CL. Burgess MR, et al. Among authors: shah np. Proc Natl Acad Sci U S A. 2005 Mar 1;102(9):3395-400. doi: 10.1073/pnas.0409770102. Epub 2005 Feb 10. Proc Natl Acad Sci U S A. 2005. PMID: 15705718 Free PMC article.

9

Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases.

Carter TA, Wodicka LM, Shah NP, Velasco AM, Fabian MA, Treiber DK, Milanov ZV, Atteridge CE, Biggs WH 3rd, Edeen PT, Floyd M, Ford JM, Grotzfeld RM, Herrgard S, Insko DE, Mehta SA, Patel HK, Pao W, Sawyers CL, Varmus H, Zarrinkar PP, Lockhart DJ. Carter TA, et al. Among authors: shah np. Proc Natl Acad Sci U S A. 2005 Aug 2;102(31):11011-6. doi: 10.1073/pnas.0504952102. Epub 2005 Jul 26. Proc Natl Acad Sci U S A. 2005. PMID: 16046538 Free PMC article.

10

Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the Aurora kinase inhibitor VX-680.

Young MA, Shah NP, Chao LH, Seeliger M, Milanov ZV, Biggs WH 3rd, Treiber DK, Patel HK, Zarrinkar PP, Lockhart DJ, Sawyers CL, Kuriyan J. Young MA, et al. Among authors: shah np. Cancer Res. 2006 Jan 15;66(2):1007-14. doi: 10.1158/0008-5472.CAN-05-2788. Cancer Res. 2006. PMID: 16424036

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

418 results

Search Page

Filters